Respiratory Infections

An English modeling study suggests level of protection decreases only very slightly over time and reminds parents to have their children up to date on all vaccinations.

The findings are from a National Foundation for Infectious Diseases (NFID) survey showing many Americans are not thinking about flu, COVID-19, RSV, or pneumococcal disease, and many respondents do not plan to get vaccinated this fall.

New research highlights a complex relationship between COVID-19 and cognitive function, suggesting that even mild infections can lead to subtle memory and attention deficits lasting at least a year.

The study estimates that vaccination efforts may have averted between 610,000 and 2.61 million deaths during the first 18 months of the rollout.

The federal agency gave the nod to FluMist nasal spray to allows individuals to administer the vaccine themselves and as a caregivers to others.

Initially authorized based on promising trial data, recent analyses raise questions about the effectiveness of nirmatrelvir/ritonavir and molnupiravir against new viral variants, particularly regarding mortality and hospitalization rates.

A large study shows a moderate benefit to taking the antimalarial therapy.

Adults with type 2 diabetes who use metformin have a 13% to 21% reduced risk of developing Long COVID or dying from COVID-19 compared to those taking other diabetes medications.

The CSL and Arcturus Therapeutics’ vaccine, ARCT-154 (Kostaive), is designed to offer protection against the JN1 strain.

The International Society for Infectious Diseases (ISID) ProMED surveillance system is a way for clinicians and interested ID stakeholders to be aware of local outbreaks and follow-up in response to get more information on them.

The organization's designation for the Bavarian Nordic’s MVA-BN (Jynneos) mpox vaccine is aimed at helping with the public health response, especially in Africa, where incidences rates continue to increase.

Ami Patel, PhD, provides insights on both technologies and how her research center, the Wistar Institute, is involved in DNA vaccine and monoclonal antibody research.

Females are more frequently affected by Long COVID than males, highlighting distinct immunological processes and hormonal variations.

Recent data and conversations with experts highlighted the increasing concern of Long COVID’s impact on the brain in patients who have been previously infected with the virus.

Internal tremors are a newly recognized and troubling symptom of Long COVID, experienced by over one-third of participants in a Yale-based study

First case this year without a documented occupational exposure to infected animals.

The Phase 1/2 study of VAX-31 demonstrated that the vaccine was well tolerated and elicited strong opsonophagocytic activity immune responses across all 31 evaluated serotypes.

Transmission to humans is limited in the US, but concerns linger, especially in the wake of the COVID-19 pandemic.

Bavarian Nordic is working to get their MVA-BN (Jynneos) mpox vaccine to those affected in African countries, as well as working towards a clinical trial for the younger pediatric population, and potential regulatory approval in Europe for adolescents.

We have complied some of our news stories and interviews from the last week to offer information on the differences between clade I and clade 2 mpox, why WHO declaring the global emergency is significant, looking at mpox in the United States, and more.

Mitch Wolfe, MD, former Chief Medical Officer of CDC, offers some insights on mpox including the benefits of declaring a global emergency, disease transmission, and considerations for both the US public and clinicians.

Scott Bertani, who is the director of Advocacy of the National Coalition for LGBTQ Health, discusses what the new mpox health declarations mean to the US, which groups are high risk, and information about the vaccine to prevent the disease.

The impact of including patients with advanced disease and the role of comprehensive care in the PALM 007 clinical trial, which evaluated the antiviral tecovirimat for treating monkeypox in the Democratic Republic of the Congo.

The Public Health Agency of Sweden reported the individual sought care at Region Stockholm and has been diagnosed with mpox caused by clade I.

4-way trial assesses non-prescription interventions, including 2 nasal sprays, for reducing seasonal respiratory illness and related antibiotic use.